BDX Stock Movement Summary Becton Dickinson (BDX) experienced a sharp repricing following announcements related to its life sciences spinoff. Key facts: Q1 FY2026 Results: - Revenue: $5.3 billion (1.6% reported growth, 0.4% FXN) - Adjusted diluted EPS: $2.91, beating consensus of $2.81 - Sales slightly above consensus of $5.15 billion Guidance Changes: - BD significantly lowered fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65 per share - This reduction reflects the anticipated separation of Biosciences and Diagnostic Solutions business combined with Waters Corporation Transaction Status: - The combination of BD's Biosciences and Diagnostic Solutions with Waters Corporation closed on February 9, 2026 - BD will receive a $4 billion cash distribution from the transaction The earnings guidance reduction drove the stock repricing despite beating current quarter expectations.
Read full analysisBDX Stock Movement Summary Becton Dickinson (BDX) experienced a sharp repricing following announcements related to its life sciences spinoff. Key facts: Q1 FY2026 Results: - Revenue: $5.3 billion (1.6% reported growth, 0.4% FXN) - Adjusted diluted EPS: $2.91, beating consensus of $2.81 - Sales slightly above consensus of $5.15 billion Guidance Changes: - BD significantly lowered fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65 per share - This reduction reflects the anticipated separation of Biosciences and Diagnostic Solutions business combined with Waters Corporation Transaction Status: - The combination of BD's Biosciences and Diagnostic Solutions with Waters Corporation closed on February 9, 2026 - BD will receive a $4 billion cash distribution from the transaction The earnings guidance reduction drove the stock repricing despite beating current quarter expectations.
Becton, Dickinson and Company (BDX) is a publicly traded company in the Healthcare sector.